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DISSERTATION ABSTRACT 
 
Jennifer Hampton Hill 
 
Doctor of Philosophy 
 
Department of Biology 
 
September 2017 
 
Title: Bacterial Regulation of Host Pancreatic Beta Cell Development 
 
 
Diabetes is a metabolic disease characterized by the loss of functional pancreatic 
beta cells. The incidence of diabetes has risen rapidly in recent decades, which has been 
attributed at least partially to alterations in host-associated microbial communities, or 
microbiota. It is hypothesized that the loss of important microbial functions from the 
microbiota of affected host populations plays a role in the mechanism of disease onset. 
Because the immune system also plays a causative role in diabetes progression, and it is 
well documented that immune cell development and function are regulated by the 
microbiota, most diabetes microbiota research has focused on the immune system. 
However, microbial regulation is also required for the development of many other 
important tissues, including stimulating differentiation and proliferation. We therefore 
explored the possibility that the microbiota plays a role in host beta cell development. 
Using the larval zebrafish as a model, we discovered that sterile or germ free (GF) larvae 
have a depleted beta cell mass compared to their siblings raised in the presence of 
bacteria and other microbes. This dissertation describes the discovery and 
characterization of a rare and novel bacterial gene, whose protein product is sufficient to 
rescue this beta cell developmental defect in the GF larvae. Importantly, these findings 
suggest a possible role for the microbiota in preventing or prolonging the eventual onset 
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of diabetes through induction of robust beta cell development. Furthermore, the loss of 
rare bacterial products such as the one described herein could help to explain why low 
diversity microbial communities are correlated with diabetes.   
This dissertation includes previously published and unpublished co-authored 
material. 
 
 
  
 
vi 
CURRICULUM VITAE 
 
NAME OF AUTHOR:  Jennifer Hampton Hill 
 
 
GRADUATE AND UNDERGRADUATE SCHOOLS ATTENDED: 
 
 University of Oregon, Eugene 
 Humboldt State University, Arcata 
 
 
DEGREES AWARDED: 
 
 Doctor of Philosophy, Biology, 2017, University of Oregon 
 Bachelor of Science, Biology, 2010, Humboldt State University 
 
 
AREAS OF SPECIAL INTEREST: 
 
 Microbiology 
 Animal Physiology and Development 
 
 
PROFESSIONAL EXPERIENCE: 
 
 Graduate Teaching Assistant, University of Oregon, September 2011 - June 2012 
  
 Research Technician, Humboldt State University, August 2009 – May 2010   
 
 
GRANTS, AWARDS, AND HONORS: 
 
Pete von Hippel Graduate Scholar Award, University of Oregon, Institute of  
Molecular Biology, 2015 
 
 Best Flash Talk, University of Oregon, Institute of Molecular Biology Retreat, 
2015 
 
 Best Poster, Zebrafish for Personalized/Precision Medicine Conference, St. 
Michael’s Hospital, Toronto, CA, 2015 
 
 National Institutes of Health (NIH) Genetics Training Grant Appointment, 
University of Oregon, 2012-2015 
 
California Institute for Regenerative Medicine (CIRM) Bridges Fellow, 
University of California San Francisco, 2010-2011 
  
 
vii 
 
 
PUBLICATIONS: 
 
Hill, JH, Franzosa, EA, Huttenhower, C, and Guillemin, K. (2016). A conserved bacterial 
protein induces pancreatic beta cell expansion during zebrafish development. eLife, 5, 
e20145. 
 
Jemielita, M, Taormina, MJ, Burns, AR, Hampton, JS, Rolig, AS, Guillemin, K, and 
Parthasarathy, R. (2014). Spatial and temporal features of the growth of a bacterial 
species colonizing the zebrafish gut. mBio vol. 5no. 6 e01751-14. 
 
Arroyo, FA, Siering, PL, Hampton, JS, McCartney, A, Hurst, MP, Wolfe, GV, and 
Wilson, MS. (2014). Isolation and characterization of novel iron-oxidizing autotrophic 
and mixotrophic bacteria from boiling springs lake, an oligotrophic, acidic geothermal 
habitat. Geomicrobiology vol. 32 no. 2. 140-157. 
 
 
 
  
 
viii 
ACKNOWLEDGMENTS 
 
This research would not exist without the profound enthusiasm and guidance of 
my mentor, Dr. Karen Guillemin, who has always encouraged the development of 
imaginative scientific questions. I would also like to thank the members of my advisory 
committee who not only helped to shape my development as a scientist, but also 
supported me as I explored post-graduate career options. Furthermore, I have had the 
pleasure of working alongside incredibly creative post-docs, technicians and fellow 
graduate students who provided training and critical insight for this work. Specifically, 
fellow graduate student Michelle Sconce has provided assistance and intellectual 
contribution for experiments in Chapter III and her continued work on this project will 
surely see fruition on several ideas presented in Chapter IV. Undergraduate, Daniel 
Derrick also provided technical assistance for many preliminary experiments that laid the 
groundwork for ideas presented in Chapter IV. Dr. James Remington, Dr. Emily 
Sweeney, and Karen Kallio were integral in the process of solving the BefA crystal 
structure presented in Chapter III. Rose Sockol is our zebrafish technician, who’s work, 
along with the entire University of Oregon Zebrafish Facility, was essential for this 
project. 
Lastly, I am grateful to members of my family, who have each been an inspiration 
to me in my graduate career.  
 
  
 
ix 
 
 
 
 
 
 
 
This work is dedicated to my mother, father, and sister. My mother’s relentless 
compassion for helping people, my father’s strong love for the natural world, and my 
sister’s limitless creativity have all manifested in this project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
x 
TABLE OF CONTENTS 
Chapter Page 
 
 
I. MICROBES, MODELS, AND MALADIES: IDEAS & TOOLS FOR THE  
   STUDY OF METABOLIC DISEASE .....................................................................  1 
 Introduction ...........................................................................................................  1 
 The Microbiota: Providing New Insight On Human Disease ...............................  2 
 
 Diabetes: A Case Study for the Disappearing Microbiota Hypothesis .................  4 
 
 Zebrafish: Modeling Microbiota and Metabolic Disease ......................................  6 
 Bridge ....................................................................................................................  11 
II. A CONSERVED BACTERIAL PROTEIN INDUCES PANCREATIC BETA  
     CELL EXPANSION DURING ZEBRAFISH DEVELOPMENT ........................  12 
 Introduction ...........................................................................................................  12 
 Results ...................................................................................................................  15 
 Discussion .............................................................................................................  30 
 Materials and Methods ..........................................................................................  34 
 Bridge ....................................................................................................................  42 
III. THE ATOMIC STRUCTURE OF BEFA REVEALS A NEW PROTEIN  
      FOLD SUFFICIENT FOR BETA CELL EXPANSION ......................................  44 
 Introduction ...........................................................................................................  44 
 Results ...................................................................................................................  47 
 Discussion .............................................................................................................  53 
 Materials and Methods ..........................................................................................  55 
 
 
 
 
  
 
xi 
Chapter Page 
 
IV. CONCLUDING REMARKS AND FUTURE DIRECTIONS .............................  58 
REFERENCES CITED ...............................................................................................  62 
  
 
xii 
LIST OF FIGURES 
 
Figure Page 
 
 
1. The microbiota is required for normal expansion of the larval beta cell mass .....  16 
 
2. Specific bacterial members of the zebrafish microbiota are sufficient to rescue  
      normal expansion of the GF beta cell mass. ..........................................................  18 
 
3. Aeromonas secretes a factor that rescues normal expansion of the GF beta  
      cell mass ................................................................................................................  21 
3S. 10165 (BefA) protein purification .........................................................................  22 
4. BefA is required for Aeromonas to induce GF beta cell expansion ......................  24 
4S. BefA confers a colonization advantage in the larval zebrafish gut ........................  24 
5. BefA facilitates beta cell mass expansion through proliferation ...........................  27 
5S. The microbiota increase beta cell neogenesis from the EPD ................................  28 
6. Homologs of BefA encoded in the human microbiome have conserved  
      function in zebrafish ..............................................................................................  29 
6S. Amino acid sequence alignment of BefA and functionally conserved  
      homologs ...............................................................................................................  30 
3.1. The structure of BefA reveals a novel protein fold containing a SYLF  
       domain ..................................................................................................................  48 
3.2. The SYLF domain of BefA is sufficient to rescue normal expansion of the  
       GF beta cell mass .................................................................................................     50 
3.3. BefA increases beta cell number of GF ex vivo larval zebrafish islets ................  52
  
 
1 
 
CHAPTER I 
MICROBES, MODELS, AND MALADIES: IDEAS AND TOOLS FOR 
THE STUDY OF METABOLIC DISEASE 
 
INTRODUCTION 
Modern humans predominantly associate microbial organisms with contagious 
disease. Since the formulation of the germ theory of disease by Pasteur and Koch in the 
late 1800s, we have taken greater and greater measures to combat the threat of “germs” 
and prevent infections. Cleanliness of both the body and the home are kept through the 
regular use of commercial antibacterial products. Thanks to the use of antibiotics and 
vaccines, the spread of microbial caused illness is now much less prevalent in societies 
with access to these medical advances, and many life-threatening bacterial infections can 
thankfully be prevented. However, there seems to be a trade off to these benefits. As the 
threat of contagion has become low, the incidence of autoimmune disease is 
unfortunately rising (Bach, 2002). Several theories involving our contemporary practices 
of cleanliness and limited exposure to microbial organisms have arisen to explain this 
phenomenon. The Hygiene Hypothesis and the subsequent Old Friend’s Hypothesis 
predict that childhood exposure to diverse microbial antigens is required for the 
development and function of a healthy immune system (Rook et al., 2004). Similarly, the 
Disappearing Microbiota Hypothesis suggests that rare microbial species, which were 
commonly associated with ancient humans, play specific and essential roles in our 
wellbeing (Blaser and Falkow, 2009). Unfortunately, due to reductions in both vertical 
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and horizontal transmission over many generations, we have slowly lost our associations 
with these important organisms (Blaser and Falkow, 2009). All of these theories suggest 
that exposure to microbes is beneficial, and that most bacteria are not agents of disease. 
In fact, by removing these “germs”, we may have lost an essential component of our 
overall health.  
 
THE MICROBIOTA: PROVIDING NEW INSIGHT ON HUMAN DISEASE 
Our association with microbes is intimate. Unlike the picture that germ theory 
paints, bacteria and viruses aren’t something that we get on us every once in a while from 
touching something dirty. Rather, we are steeped in microbes from the day of our birth 
(Mueller et al., 2015), and this assemblage of microscopic beings that inhabit our bodies 
and those of other animals is collectively called the microbiota. It is comprised of a 
diverse array of taxonomic groups including species of bacteria, fungi, single celled 
eukaryotes, and viruses (Morgan et al., 2013). This complex collection of organisms is 
often referred to as a community, as different members perform different functions that 
contribute to its overall ecological health (Huttenhower et al., 2012). In the case of the 
microbiota, the ecological environment is the host animal, which is in turn reliant upon 
the functions of this microbial community for its own health (McFall-Ngai et al., 2013). 
So far, the majority or our understanding about the functions of the microbiota comes 
from studying bacteria. In 2008, the National Institutes of Health (NIH) launched the 
human microbiome project (HMP). The initial phases of this project involved massive 
bacterial sampling and sequencing efforts focused on identifying the species associated 
with different sites of the human body in both health and disease (Integrative HMP 
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(iHMP) Research Network Consortium, 2014). These and many other metagenomic 
studies revealed that the community membership of host-associated bacteria often differs 
significantly between healthy and sick people, with decreased taxonomic diversity being 
a common feature of disease states (DeGruttola et al., 2016). Animal modeling of 
disease-associated microbiota provides evidence that the microbial community is capable 
of causing or perpetuating the disease (Gülden et al., 2015; Ley et al., 2006; McFall-Ngai 
et al., 2013). The transformation from a healthy to a disease-causing community is called 
dysbiosis (Levy et al., 2017), and identifying the bacterial changes that occur in dysbiotic 
communities is a current focus of microbiota research that holds promise for developing 
many new disease treatments (Petersen and Round, 2014).    
The revelation that the microbiota is an understudied and critical component to 
animal health has resulted in a wave of publications that collectively implicate an almost 
unimaginable diversity of requirements for bacteria or other microbes in animal health. 
However, these discoveries become less surprising when we consider the fact that 
animals evolved in a world dominated by microbial organisms (McFall-Ngai et al., 
2013). These tiny creatures ruled and shaped our environment for billions of years before 
the evolution of multicellular life (Grosberg and Strathmann, 2007). To survive in this 
microbial environment, eukaryotes must have evolved mechanisms to “eavesdrop” on 
microbes for important information about their surrounding ecosystem, perhaps through 
the detection of secreted microbial molecules. For example, nutritional availability can be 
interpreted through the metabolic by-products of bacteria breaking down various carbon 
sources. One possible scenario is that multicellular life greatly benefited by “listening in” 
on the activities of microbes, and as a result, became dependent upon them for important 
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processes. Today, we know that animals rely on bacteria for regulating their own 
metabolic homeostasis (Nicholson et al., 2012). When these important bacterial functions 
go missing from the microbiota, the host is thrown out of balance and oftentimes 
succumbs to disease (DeGruttola et al., 2016).  
 
DIABETES: A CASE STUDY FOR THE DISAPEARING MICROBIOTA 
HYPOTHESIS 
Diabetes is a group of metabolic diseases classified by the loss of functional 
insulin, which most commonly manifests through autoimmune destruction of beta cells or 
insulin resistance in either type 1 or type 2 diabetes respectively (Tai et al., 2015). These 
diseases are prominent human ailments that are strongly correlated with decreased 
microbiota diversity (Brown et al., 2011; Giongo et al., 2011; Kostic et al., 2015). In 
Type 1 diabetes (T1D), monozygotic twins have a discordance rate of about 50%, 
implicating a prominent environmental cause for the disease in addition to genetic 
predisposition (Akerblom et al., 2002). Intriguingly, the environmental risk factors 
correlated with diabetes are largely modern practices of developed countries, which 
include a high use of antibiotics, anti-bacterial cleansers and soaps, vaccines, cesarean 
sections, and a high fat diet (Gülden et al., 2015). These are all factors predicted to 
contribute to our declining interaction with important microbes as described by the 
Disappearing Microbiota Hypothesis (Blaser and Falkow, 2009). In the case of type 1 
diabetes (T1D), the loss of microbial-associated diversity occurs prior to disease onset, 
often before the age of three years, and is believed to be at least partially causative 
(Kostic et al., 2015). Animal models have suggested that early alterations to the gut 
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microbiota, during important developmental events, can impact the health of the host 
later in life (Cox et al., 2014). In rodent models of T1D, treatment with antibiotics during 
early life, results in greater incidence and earlier onset of disease than in genetically 
identical siblings not treated with antibiotics (Brown et al., 2016; Candon et al., 2015). 
During this early age, beta cell mass is expanding through avenues of both differentiation 
and proliferation in order to establish a robust insulin production center to efficiently 
regulate glucose homeostasis into adulthood (Gregg et al., 2012; Hesselson et al., 2009). 
Insufficient beta cell mass expansion can contribute to diabetes onset (Berger et al., 2015; 
Figliuzzi et al., 2010) in rodents, and we should investigate whether there is a connection 
between this process and the microbiota in order to develop new therapeutic approaches 
to diabetes treatment and prevention. 
Unfortunately, rates of diagnoses for both types of diabetes have been rising 
substantially over the last few decades (Tai et al., 2015), making the need for effective 
therapeutics greater than ever. Because of the loss of insulin, T1D and late stage T2D 
have no cure and are much more difficult to control. Currently, the only effective 
treatments are exogenous insulin injection and islet transplantation (Farney et al., 2016). 
Insulin injection is only effective at managing symptoms, and requires vigilant 
monitoring of blood glucose levels. Islet transplantation is only moderately effective, 
with roughly 50% of recipients remaining insulin independent up to 5 years post 
transplant (Farney et al., 2016). Furthermore, cadaver islet tissue available for 
transplantation is rare, and once transplanted, the foreign beta cells are still at the mercy 
of the patient’s malfunctioning immune system in the case of T1D (Farney et al., 2016; 
Johannesson et al., 2015). Alternatively, many avenues of research are focused on 
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expanding a patient’s endogenous beta cell population in order to restore insulin supply 
(Johannesson et al., 2015). There are two primary mechanisms of normal beta cell 
expansion: neogenesis (differentiation from progenitors) and self-proliferation 
(Johannesson et al., 2015). Researchers hope that a better understanding of these regular 
developmental events can lead to treatments that will induce the expansion of the 
functional beta cell mass in vivo. Because of the strong correlation between early beta 
cell expansion and dysbiosis, research into whether or not there is a microbial role in beta 
cell development is worthwhile and could provide new avenues for diabetes treatments. 
Furthermore, in a less diverse community, loss of bacterial functions important for host 
beta cell development could result in reduced beta cell mass and render some individuals 
more susceptible to diabetes. 
 
ZEBRAFISH: MODELING MICROBIOTA AND METABOLIC DISEASE 
In order to understand how dysbiosis contributes to disease, we need to study the 
molecular mechanisms that contribute to bacterial mediated changes in host physiology. 
Metagenomic-sequencing efforts inform us about the major bacterial lineages present in a 
given community, but they can not be used to dissect the complex molecular interactions 
that occur between the microbiota and its host environment. Techniques developed for 
the derivation of completely sterile or “germ free” model organisms have allowed 
researchers to make substantial headway in learning about important host-microbe 
interactions (McFall-Ngai et al., 2013). Powerful gnotobiotic techniques have been 
developed in several animal models, including mice, zebrafish, stickleback, flies, hydra, 
and even the ancestor of multicellular organisms, Choanoflagellates. (McFall-Ngai et al., 
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2013; Milligan-Myhre et al., 2016). Studies in these organisms have revealed surprising 
roles for bacteria in host biology, most notably including in development, immune system 
function, and metabolic homeostasis (McFall-Ngai et al., 2013). Each of these different 
animal models brings its own unique advantages and tools to microbiota research.  
The zebrafish offers specific strengths for modeling human metabolic diseases of 
host-microbiota interactions. Historically, it has served is an excellent model for 
observing and imaging vertebrate development thanks to the strong collection of genetic 
tools that have been developed in this platform. Zebrafish also have extremely high 
fecundity, relatively low maintenance costs, and are simple to derive germ free in large 
numbers (2017). Furthermore, the intestinal microbiota of the zebrafish is well described, 
and culture isolates are available that are representative of most of the major genera 
identified by sequencing analyses (Stephens et al., 2015).  
Metabolic homeostasis is perhaps influenced by the microbiota in more ways than 
any other host process. Conveniently, many of the same attributes that make zebrafish a 
strong developmental model, such as larval transparency and conserved organ function, 
also present the opportunity to study metabolic function (Gut et al., 2017). For instance, a 
variety of fluorescent lipophilic dyes are available that allow for the tracking of fatty 
acids and lipid accumulation in vivo (Santoro, 2014). Several mutant lines provide 
models that recapitulate aspects of human metabolic diseases (Seth et al., 2013), and 
established transgenic lines allow for the observation of metabolically important cell 
types (Gut et al., 2017). Glucose metabolism and gluconeogensis can be tracked to give 
an accurate readout of endocrine pancreas and liver function respectively (Andersson et 
al., 2012; Gut et al., 2013). Even overall metabolic rate and oxidative stress can also be 
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determined in the zebrafish using commercial kits that function on both live and fixed 
cells (Santoro, 2014). Since the knowledge of the vast significance of microbes for host 
health is relatively new, only a handful of important studies have so far utilized these 
zebrafish tools to study the interplay between bacteria and host metabolic function. 
However, the following early observations illustrate that the zebrafish is a powerful 
model that can be utilized for furthering our understanding of the mechanisms that give 
rise to altered host physiology and subsequently disease.  
Fat absorption and storage is one area of study where the strengths of the 
zebrafish have been shown to be particularly amenable to interrogate the interactions 
between bacteria and host physiology. Not only can researchers visualize lipid 
accumulation defects (Santoro, 2014), they can track adipose tissue development 
(Minchin and Rawls, 2017). The Rawls lab has studied the role of the microbiota in 
regulating intestinal lipid absorption from the diet. They showed that bacteria induce the 
formation of lipid droplets within the intestinal epithelia through at least two separate 
mechanisms (Semova et al., 2012a). First, the size of lipid droplets was regulated by the 
presence of microbes, and second, during feeding Firmicutes species were sufficient to 
cause an increase in the formation of the number of lipid droplets within the epithelia 
(Semova et al., 2012a). The authors also showed that this increased lipid accumulation 
resulted in increased export of lipids to systemic tissues, suggesting that microbial 
composition can regulate the efficiency and rate of lipid absorption (Semova et al., 
2012b). It will be valuable to continue studies like this one to see if changes in the 
microbiota result in altered lipid transport to various regional ATs, in order to eventually 
understand how we can utilize bacterial species to modulate fat absorption to attenuate 
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metabolic diseases such as obesity and cachexia. To aid in this goal, Minchin and Rawls 
recently released a detailed characterization of zebrafish adipose tissue (AT) that includes 
a comprehensive description of the anatomical location, development, and size of 34 
adipose tissue types in the zebrafish (Minchin and Rawls, 2017). The authors go on to 
compare adipose tissues between common lab-reared fish strains and evaluate the general 
morphological changes of AT to a high fat diet (Minchin and Rawls, 2017). Alterations to 
lipid accumulation in regional AT types is a significant risk factor leading to obesity and 
diabetes and this new characterization will allow researchers to explore the specific ways 
in which adipose tissue is influenced by microbial factors (Minchin and Rawls, 2017).  
Diet is an important factor in nutrient availability and variation in host diet also 
plays an important role in how microbes can influence host metabolic processes 
(Nicholson et al., 2012). For instance, a recent study by Gou and colleagues using a larval 
zebrafish model found that a diet of nucleotides led to decreased metabolic rate through 
two microbiota-mediated mechanisms. First, microbial suppression of fiaf gene 
expression led to decreased fatty acid (FA) oxidation in the muscle and liver (Guo et al., 
2017). The authors also saw decreased inflammation in the head kidney, suspected to 
further reduce metabolic rate through decreased immune cell activity (Guo et al., 2017). 
They showed that these phenotypes corresponded to a higher percentage of obligate 
anaerobes within the microbiota (Guo et al., 2017). Further studies should focus on 
identifying the microbial mechanism required for this altered host gene expression, and 
determining whether these changes alter early development of the larval muscle or liver.  
Several studies from the Chen lab have also described an effect of diet on 
zebrafish metabolism. They originally observed that a variety or rich carbohydrate 
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sources, including glucose and egg yolk, in the larval diet resulted in altered glucose 
regulation (Maddison and Chen, 2012). They later found that greater glucose availability 
from these high carbohydrate diets caused an increased demand for insulin, which was 
alleviated by an eventual increase in total pancreatic beta cells, the source of insulin in 
the body (Li et al., 2015). Subsequently they implicated FGF1 signaling in the induction 
of beta cell differentiation, showing that diet and development of this important cell 
population are linked (Li et al., 2015). The authors did not look at the role of the 
microbiota in this process, however this would be an easy question to investigate given 
the ability to study both microbes and beta cell development in the larval zebrafish (Bates 
et al., 2006; Kinkel and Prince, 2009). Furthermore, as explained earlier, because beta 
cell function is lost in both T1 and T2D, uncovering novel mechanisms of beta cell 
renewal is a primary goal for the development of diabetes treatments in order to restore 
normal-glycaemia without the use of exogenous insulin (Johannesson et al., 2015).  
We have outlined the work that has laid a strong foundation for the use of 
zebrafish to study the interface between metabolism and associated microbes. Although 
there are few studies to cover thus far, it is clear that the potential for continued research 
in these areas, as well as new research into other categories of metabolic function would 
benefit from this model system. Toward this end, this dissertation will utilize the larval 
zebrafish system in order to investigate a role for host-associated bacteria in beta cell 
regulated glucose metabolism. 
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BRIDGE  
Research using gnotobiotic zebrafish has helped to illustrate the important role 
that associated bacteria play in host developmental and metabolic processes (Guo et al., 
2017; Semova et al., 2012a). In Chapter 1, we reviewed the studies that have utilized 
zebrafish to investigate the interactions between metabolism and microbes. In the field of 
development, our lab has shown that bacteria are required for enterocyte proliferation 
(Cheesman et al., 2011) and goblet cell differentiation (Bates et al., 2006). However, little 
work has been done in any model organism to look at the influence of bacteria on the 
development of other systemic tissues that play a large role in metabolic homeostasis, 
such as the pancreas. Given the connections between early beta cell expansion, loss of 
microbial diversity, and diabetes onset in humans, this cell population is also an 
important area of study for human health. In the next chapter, we use the tools available 
in the zebrafish system to investigate whether bacteria play a role in beta cell 
development and glucose regulation. 
 
Chapter II of this dissertation contains previously published, co-authored material 
reproduced herein with the permission from Jennifer Hill and Karen Guillemin.  
Chapter III contains unpublished co-authored material presented with permission 
from S. James Remington, Emily Sweeney, and Karen Kallio.  
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CHAPTER II 
A CONSERVED BACTERIAL PROTEIN INDUCES PANCREATIC 
BETA CELL EXPANSION DURING ZEBRAFISH DEVELOPMENT 
Reproduced with permission from Hill JH, and Guillemin K. Copyright 2016, eLife. I 
was the primary contributor to this work, carrying out the experiments, analysis and 
writing. My mentor and principal investigator on the paper, K. Guillemin, contributed to 
experimental design, analysis and writing. Authors E. Franzosa and C. Huttenhower 
provided unique expertise for Figure 6, panels A and B. 
 
INTRODUCTION 
 Host-associated microbes play important roles in the development of 
animal digestive tracts (Bates et al., 2006; Semova et al., 2012a; Sommer and Bäckhed, 
2013). Using the gnotobiotic zebrafish model, our group has shown previously that 
resident microbes promote host processes in the developing intestine such as epithelial 
differentiation (Bates et al., 2006) and proliferation (Cheesman et al., 2011). The role of 
microbes in the development of other digestive organs remains underexplored, despite the 
fact that many diseases in peripheral digestive organs are correlated with microbial 
dysbiosis (Chang and Lin, 2016; Gülden et al., 2015). The ability to manipulate resident 
microbes in the larval zebrafish (Milligan-Myhre et al., 2011), combined with the optical 
transparency and sophisticated genetic tools of the zebrafish model, make it a powerful 
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platform to investigate this question. Here, we use gnotobiotic zebrafish to demonstrate a 
role for resident microbes in promoting pancreatic beta cell development.  
The zebrafish has a well-characterized program of beta cell development, which is 
highly conserved with that of mammals (Kinkel and Prince, 2009). In the zebrafish 
embryo, initial beta cells arise from precursors within the dorsal and ventral pancreatic 
buds (Biemar et al., 2001; Field et al., 2003; Wang et al., 2011). The two buds fuse by 52 
hours post fertilization (hpf), and give rise to the fully fated pancreas with only a single 
islet of hormone-secreting endocrine cells, by 3 days post fertilization (dpf) (Biemar et 
al., 2001; Field et al., 2003; Kumar, 2003). Coinciding with the approximate time of 
larval emergence from the chorion by 3 dpf, these newly fated beta cells begin to expand 
(Chung et al., 2010; Dong et al., 2007; Hesselson et al., 2009; Kimmel et al., 2011; Moro 
et al., 2009). beta cells derived from the dorsal bud become quiescent, while ventral bud 
derived beta cells begin to undergo expansion via mechanisms of both proliferation and 
neogenesis (Hesselson et al., 2009). Between 3 and 6 dpf, the number of beta cells within 
the primary islet will almost double (Moro et al., 2009). Intestinal colonization with 
microbes occurs concurrently with this early larval period of beta cell expansion. 
Following development of the gut tube within the sterile embryo, the intestine of the 
emergent larva becomes open to the environment at both the mouth and the vent by 3.5 
dpf, allowing for inoculation by environmental microbes (Bates et al., 2006). Within the 
larval gut, bacteria proliferate rapidly, such that a single species in mono-association can 
reach the luminal carrying capacity within several hours (Jemielita et al., 2014).  
Human post-natal beta cell expansion also occurs concurrently with intestinal 
tract colonization by commensal microbes. In utero, beta cells are produced via 
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differentiation from progenitors (Georgia et al., 2006; Stanger et al., 2007) and at birth 
this newly fated cell population begins to expand by self-proliferation (Georgia and 
Bhushan, 2004; Gregg et al., 2012; Kassem et al., 2000; Teta et al., 2007). beta cell 
proliferation rates peak at 2 years of age and then steadily decline (Gregg et al., 2012). 
By 5 years of age, most of the beta cell mass has become slow cycling and will not 
expand significantly again unless stimulated by elevated metabolic demands, such as 
obesity or pregnancy. At birth, infants are exposed to their mothers’ vaginal, fecal and 
skin associated microbes, which immediately begin to colonize the neonatal intestine 
(Biasucci et al., 2010; Dominguez-Bello et al., 2010; Palmer et al., 2007). By 3 years of 
age, the composition and complexity of the microbiota typically resembles that of an 
adult associated community (Murgas Torrazza and Neu, 2011; Palmer et al., 2007; 
Yatsunenko et al., 2012). However, factors such as diet, birth mode and antibiotic 
exposure can result in reduced microbial taxonomic diversity during these early years of 
life (Mueller et al., 2015). Notably, factors that reduce microbiota diversity are also 
associated with increased risk for diabetes mellitus (Knip et al., 2005). Loss of beta cell 
function through autoimmunity results in abnormal glucose homeostasis and is the cause 
of type 1 diabetes (T1D) in humans. Recent studies have shown that decreased taxonomic 
diversity of the intestinal microbiota is correlated with T1D (Brown et al., 2011; Giongo 
et al., 2011). Indeed, loss of bacterial diversity precedes the onset of T1D in children, and 
may play a causative role in disease (Kostic et al., 2015).  
To our knowledge, no one has yet investigated a role for the gut microbiota in the 
development of pancreatic beta cells. Communication between the intestine and the 
pancreas is critical for overall homeostasis. The two organs are therefore connected 
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physically, metabolically, and developmentally in order to carry out their essential 
functions. We propose that this established and important connection might also mediate 
the influence of resident microbes on developmental processes in the pancreas. Here we 
examine the effects of microbial colonization on initial expansion of zebrafish primary 
islet beta cells. We find that beta cell mass expansion, up to at least 6 dpf, is promoted by 
the presence of the microbiota. Using a culture collection of zebrafish intestinal bacteria, 
we show that certain strains can restore beta cell expansion in germ free (GF) fish. We 
report the discovery of a secreted protein, shared among these strains and named herein 
beta cell expansion factor A (BefA) that is sufficient to recapitulate this effect. Homologs 
of the befA gene are present in the genomes of a subset of human intestinal bacteria, and 
we show that two of the corresponding proteins share BefA’s capacity to induce beta cell 
expansion in zebrafish.  
 
RESULTS 
The microbiota is required for normal expansion of the larval beta cell mass 
To investigate a possible role for the microbiota in pancreas development and 
specifically in beta cell expansion, we quantified total beta cells in GF and conventionally 
reared (CV) Tg(-1.0insulin:eGFP) fish (diIorio et al., 2002) at 3, 4, 5 and 6 dpf (Figure 
1A, Figure 1 – source data 1). The number of beta cells in CV fish increased steadily 
from 3 to 6 dpf (Figure 1A). However, the average number of beta cells in GF fish 
remained static over this time (Figure 1A). Furthermore, at 6 dpf, the overall structure of 
beta cells within the primary islet also appeared much less densely packed in GF than in 
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CV fish (Figure 1B). This effect is not likely to be due to changes in initial differentiation 
of the beta cell population since the total number of beta cells is not different between GF 
and CV fish at 3 dpf (Figure 1A), a time at which exposure to bacteria is also limited.  
Because insulin from beta cells functions to reduce levels of circulating glucose, 
we tested whether the beta cell deficiency in GF larvae at 6 dpf affected the metabolic 
function of the fish by measuring free glucose levels. The amount of glucose detected in 
GF fish was significantly higher than in CV fish (Figure 1C, Figure 1 – source data 2). 
These data suggest that GF fish, with a paucity of beta cells, are less efficient at 
importing and processing glucose from the blood due to lower levels of circulating 
insulin. This is consistent with previous studies showing free glucose levels in zebrafish 
larvae to be correlated with beta cell numbers (Andersson et al., 2012).  
 
Figure 1. The microbiota is required for normal expansion of the larval beta cell 
mass (next page) 
(A) Total number of beta (β) cells per larva in GF (white box plots) and CV (grey box 
plots) fish at 3, 4, 5 and 6 dpf. In this, and in all subsequent figures, CV data are shown in 
grey box plots, and GF data, or statistically similar treatment groups, are shown in white 
box plots. In all relevant panels and remaining figures, box plot whiskers represent the 
95% confidence interval of the data set. Single factor ANOVA indicates that 
gnotobiology of the fish was significant in determining the number of beta cells present 
(F7=9.01, p=1.45e-8). Labels a, ab and b indicate results of post hoc means testing 
(Tukey). The difference between GF and CV cell counts became significant at 6 dpf (t=-
5.91, p<0.001). (B) Representative 2D slices from confocal scans through the primary 
islets of 6 dpf CV and GF Tg(-1.0insulin:eGFP) larvae. Each slice is taken from the 
approximate center of the islet structure. Insulin promoter expressing beta cells are in 
green and nuclei are blue. Scale bar = 40µM. (C) Average amount of glucose (pmol) per 
larva aged 6 dpf (* t17=-3.65, p<0.01). 
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Only specific bacterial members of the zebrafish microbiota are sufficient to rescue 
normal expansion of the GF beta cell mass  
We developed an experimental timeline, depicted in Figure 2A, to test the 
capacity of individual zebrafish bacterial isolates to induce beta cell expansion. We 
derived embryos GF at 0 dpf and allowed them to develop in this environment until after 
hatching. At 4 dpf, when the GF larvae have a patent gut tube, we inoculated them with 
defined microbes and/or microbial derived products by adding these directly to the 
embryo media. The fish were incubated with the treatment of interest for 48 hours before 
analysis of the beta cell mass at 6 dpf.  
We found that we could rescue beta cell numbers to CV levels by the addition of 
non-sterile, normal fish tank water to GF larvae at 4 dpf (Figure 2B, Figure 2 – source 
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data 1), suggesting that development of the normal number beta cells is dependent upon 
microbes or microbial-derived products present in the water. We next inoculated 4 dpf 
GF larvae with a selection of bacterial isolates from the zebrafish intestine (Stephens et 
al., 2015) as well as one other related strain (Bomar et al., 2013). We prioritized bacterial 
strains that were capable of forming robust mono-associations with larvae between 4 and 
6 dpf, as measured by the number of bacteria found within the gut at 6 dpf (Figure 2C). 
We found that mono-association with three different species of the genus Aeromonas and 
one species of the genus Shewanella was sufficient to rescue GF beta cell numbers to 
levels observed in CV fish (Figure 2B, Figure 2 – source data 1). Importantly, other 
isolates such as Vibrio sp. and Delftia sp. were not sufficient to rescue this phenotype 
(Figure 2B, Figure 2 – source data 1), indicating that only specific members of the 
microbiota are capable of inducing expansion of the beta cell mass. 
 
Figure 2. Specific bacterial members of the zebrafish microbiota are sufficient to 
rescue normal expansion of the GF beta cell mass. (next page) 
(A) Experimental timeline for all subsequent zebrafish experiments, unless stated 
otherwise. Experimental manipulations are denoted by red text. Important zebrafish 
developmental events are denoted by black text. (B) Quantification of beta cells in CV, 
GF and GF larvae treated at 4 dpf with either non-sterile tank water (XGF) or mono-
associated with a specific bacterial strain. Bacterial mono-associations are labeled by 
genus. Different Aeromonas sp are labeled with a number (1, 2 or 3). *p<0.05, **p<0.01, 
***p<0.001: Denotes treatment that is significantly different than GF by Tukey analysis. 
Additionally, here and in all subsequent figures, significant data sets (p<0.05 when 
compared to GF) are also highlighted as green box plots. (C) Bacterial isolates of the 
zebrafish gut and related strains are capable of forming mono-associations with larvae 
from 4 to 6 dpf. Quantification of the colony forming units (CFUs) per gut for each 
bacterial strain, assayed after 48-hour exposure to GF larvae. Dashed line denotes the 
limit of detection. 
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Aeromonas secretes a factor that rescues normal expansion of the GF beta cell mass 
Bacterial interactions with host organisms often involve secreted molecules. To 
test whether a secreted bacterial factor(s) could influence beta cell expansion, we 
harvested cell free supernatant (CFS) from overnight cultures of each Aeromonas strain 
shown to rescue beta cell expansion (Figure 2B) and added these to GF larvae at 4 dpf. 
For each of the three strains of Aeromonas tested, the CFS alone was able to restore beta 
cell numbers in GF fish (Figure 3A, Figure 3 – source data 1), indicating that a secreted 
factor (or factors) produced by these bacteria is (are) sufficient to induce beta cell 
expansion. As a control, we also treated GF fish with CFS from a Vibrio sp. isolate, 
which colonized the zebrafish gut (Figure 2C, *), but did not induce beta cell expansion 
(Figure 2B, *). We found the number of beta cells in fish receiving Vibrio CFS was not 
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significantly different from that of GF fish (Figure 3A, Figure 3 – source data 1). 
Furthermore, the capacity to induce increased beta cell numbers was lost when the 
Aeromonas 1 (A. veronii) CFS sample was treated with proteinase K (Figure 3A, Figure 3 
– source data 1), indicating that our secreted factor(s) of interest was likely to be a 
protein. Because of existing genetic reagents available for the A. veronii strain (Bomar et 
al., 2013), and its capacity to modulate traits of gnotobiotic zebrafish and other hosts 
(Bates et al., 2006; Cheesman et al., 2011; Graf, 1999; Rolig et al., 2015), we focused on 
this strain for the remainder of our analysis.  
To narrow down the list of candidate proteins secreted by A. veronii, we tested 
whether the activity was present in the CFS of an A. veroniiΔT2SS mutant strain (Maltz and 
Graf, 2011) lacking a functional type 2 secretion system (T2SS), one of the major protein 
secretion pathways of Gram-negative bacteria. Despite the fact that it has a reduced 
secretome, CFS harvested from the A. veroniiΔT2SS strain was sufficient to rescue GF beta 
cell numbers (Figure 3A, Figure 3 – source data 1). Conveniently, this finding 
significantly decreased the number of candidate secreted A. veronii proteins with beta cell 
expansion capacity. This result also suggested that our protein(s) of interest was secreted 
through an alternative mechanism.  
We next used ammonium sulfate precipitation to further separate proteins within 
the A. veroniiΔT2SS CFS. Each of the fractions was able to increase beta cells in GF fish 
(Figure 3B, Figure 3 – source data 2), suggesting that either A. veroniiΔT2SS produces 
multiple proteins with this activity, or that the effector was present to some extent within 
each fraction. Since the 60-80% fraction was able to induce the greatest increase in beta 
cell numbers (Figure 3B), we used mass spectrometry to analyze the content of this 
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fraction, which led to identification of 163 proteins. To identify promising candidates 
from this list, we took advantage of the fact that our zebrafish-associated bacterial 
isolates, for which we have draft genome sequences (Stephens et al., 2015), differed in 
their capacity to induce beta cells (Figure 2B). Using basic local alignment search tool 
(BLAST) we identified those proteins from our candidate list that were, first, predicted to 
be encoded by the genomes of the four bacterial strains with beta cell expansion capacity, 
and second, absent from the strains lacking this capacity. Our analysis identified one 
single candidate gene, denoted by the locus tag, M001_10165 (10165), predicted to 
encode a putative protein of 261 amino acids. Consistent with the candidate protein being 
found in the CFS, the putative protein contained a predicted N-terminal secretion 
sequence. 
 
Figure 3. Aeromonas secretes a factor that rescues normal expansion of the GF beta 
cell mass. (next page) 
(A) Total beta cell numbers in GF, CV and GF fish treated at 4 dpf with different cell free 
supernatant (CFS) samples. “Aero.” refers to bacteria of the genus Aeromonas, with each 
number (1, 2, 3) denoting a separate species. “+ PK” indicates proteinase K addition to 
the CFS sample prior to treatment. *p<0.05, **p<0.01, ***p<0.001: Denotes treatment 
that is significantly different than GF by Tukey analysis. (B) Total beta cell numbers in 
CV, GF and GF fish treated at 4 dpf with separate ammonium sulfate fractions (% AS) 
prepared from the Aeromonas 1ΔT2SS CFS. Note that the 60-80% ammonium sulfate 
fraction resulted in the greatest increase in beta cell numbers. (C) Total beta cells in GF, 
CV and GF fish treated with purified protein. 10165 represents purified protein from the 
M001_10165 locus. (D) Representative 2D slices from confocal scans through the 
primary islets of GF, CV and 10165 protein treated Tg(-1.0insulin:eGFP) 6 dpf larvae. 
Insulin promoter expressing beta cells are shown in green and nuclei are blue. Scale bar = 
40µM. 
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To test whether 10165 encoded the secreted protein responsible for inducing beta 
cell expansion, we cloned the gene into an inducible expression vector in E. coli strain 
BL21, which contains no 10165 homologues in its genome. We expressed and purified 
the 10165 protein to homogeneity, as confirmed by SDS-page gel electrophoresis (Figure 
3 – figure supplement 1). Purified protein was added to flasks of 4 dpf GF zebrafish 
larvae. This treatment was sufficient to rescue beta cell numbers to CV levels by 6 dpf 
(Figure 3C, Figure 3 – source data 3). The islets of larvae treated with the purified protein 
were visibly expanded compared to those of GF animals (Figure 3D). Therefore, we have 
named this protein beta cell expansion factor A (BefA) after its observed activity in 
zebrafish. 
 
Figure 3S – figure supplement 1.10165 (BefA) protein purification. (next page) 
SDS-page gel image showing subsequent steps in the purification of BefA (black 
arrowhead) from E. coli cell lysate; lane 1: ladder, lane 2: cell lysate after IPTG 
induction, lane 3: supernatant from cell lysate after addition of nickel beads, lanes 4-7: 
elutions of BefA from beads. 
  
 
23 
 
 
 
BefA is required for Aeromonas to induce GF beta cell expansion  
To determine whether the befA (10165) locus is necessary for A. veronii to induce 
an increase in beta cell numbers, we generated an A. veroniiΔbefA mutant strain by 
replacing the coding region of befA with a chloramphenicol resistance gene. To ensure 
that the loss of the befA gene would not affect the ability of A. veronii to form mono-
associations with larvae, we performed growth and colonization assays and saw no 
deficiency in either the in vitro growth rate (Figure 4 – figure supplement 1A) or the 
ability of A. veroniiΔbefA to colonize the GF intestine compared to the wild-type (WT) 
strain (Figure 4A). However, when inoculated in a 1:1 ratio together with A. veroniiWT, 
the A. veroniiΔbefA strain showed a small yet reproducible fitness disadvantage as 
measured by colonization level and competition index after 48 hours (Figure 4 – figure 
supplement 1B, C). This result indicates that BefA confers some colonization benefit for 
A. veronii within the larval gut. 
GF fish were mono-associated with the A. veroniiΔbefA strain, or treated with its 
CFS from 4 to 6 dpf. Neither treatment was sufficient to rescue beta cell numbers to CV 
levels (Figure 4B, Figure 4 – source data 1). However, mono-associations of A. 
veroniiΔbefA could be complemented in trans with either CFS from A. veroniiWT or purified 
BefA protein, which resulted in restoration of the beta cell population (Figure 4B, Figure 
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4 – source data 1). Taken together, these data demonstrate that the BefA protein is 
necessary in an A. veronii mono-association for early beta cell expansion and suggests 
that A. veronii only produces a single effector of host beta cell expansion.  
 
Figure 4. BefA is required for Aeromonas to induce GF beta cell expansion.  
(A) Quantification of the colony forming units (CFUs) per gut in GF fish mono-
associated (MA) with either wild type (WT) or mutant (ΔbefA) A. veronii strains for 48 
hours. Dashed line denotes the limit of detection (B) Total beta cells in GF fish that have 
been mono-associated with ΔbefA, treated with CFS from either WT or ΔbefA, treated 
with purified BefA, or have been inoculated with a combination of these. **p<0.01, 
***p<0.001: Denotes treatment that is significantly different than GF by Tukey analysis. 
 
 
 
Figure 4S – figure supplement 1. BefA confers a colonization advantage in the larval 
zebrafish gut. (next page) 
(A) Growth rates of A. veroniiWT (black trace) and A. veroniiΔbefA (grey trace) in vitro. 
Density measurements (OD600) were taken every half hour for 25 hours on three replicate 
cultures grown in Lauria broth. (B) Resulting CFU’s of A. veroniiWT (WT) and A. 
veroniiΔbefA (ΔbefA) within the 6dpf larval gut after inoculation with a 1:1 ratio of each 
strain at 4 dpf. Dashed line denotes the limit of detection. (C) Competitive index (CI) 
calculation for data within panel B. CI value was calculated for each fish (n=22) by 
dividing the ratio of mutant to WT bacteria within each gut by 6 dpf, divided by the ratio 
of mutant to WT bacteria used to inoculate the fish at 4 dpf. A one-sample t-test indicates 
that the mean CI value is significantly less than 1 (dashed line) (***t21=-3.21, p<0.0001.) 
A CI value of 1 is expected if no competition exists. 
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BefA facilitates beta cell expansion by inducing proliferation  
Proliferation is the primary mode of human neonatal beta cell expansion (Gregg et 
al., 2012; Kassem et al., 2000; Teta et al., 2007). In 4-6 dpf zebrafish larvae, proliferation 
also contributes to beta cell expansion (Field et al., 2003; Hesselson et al., 2009; Moro et 
al., 2009). Therefore, we investigated whether CV larvae had higher levels of beta cell 
proliferation than GF larvae. 4 dpf larvae were treated with the thymadine analog, 5-
ethynyl-2’-deoxyuridine (EdU) for 48 hours to mark cells that underwent proliferation 
during this time window. We found that, by 6 dpf, CV larvae had significantly more EdU 
labeled insulin-expressing cells than GF larvae (Figure 5A, B, Figure 5 – source data 1). 
Next we asked whether treatment of GF larvae with BefA was sufficient to restore beta 
cell proliferation to CV levels. We found that BefA-treated GF larvae had EdU 
incorporation similar to CV fish and significantly greater than GF (Figure 5A, B, Figure 5 
– source data 1). CFS from our A. veroniiΔbefA strain was not sufficient to increase 
proliferation rates in GF fish (Figure 5B, Figure 5 – source data 1). Our results show that 
BefA is sufficient to increase cell proliferation that gives rise to an expanded beta cell 
population during early larval development. Furthermore, BefA seems to be the only 
product of the A. veronii CFS that is capable of inducing this cell proliferation.  
  
 
26 
In zebrafish larvae, both the proliferation of existing beta cells as well as the 
proliferation of progenitors contribute to the expansion of beta cells that occurs between 
4 and 6 dpf (Dong et al., 2007; Field et al., 2003). Because our 48-hour EdU pulse 
labeled β cells born from both events, our experiment did not distinguish the exact cell 
population undergoing proliferation in response to BefA. Due to their low rates of 
proliferation, dividing β cells are difficult to detect without pulse labeling. Neogenesis of 
β cells from progenitors is also rare, but can be detected as the appearance of insulin 
positive cells in the extra-pancreatic duct (EPD) (Dong et al., 2007; Hesselson et al., 
2009). We quantified insulin expressing cells in the EPD in 6 dpf CV and GF larvae. In a 
survey of over 500 Tg(-1.0insulin:eGFP) larvae, we found a slight but significant 
increase in EPD-localized insulin expressing cells in CV versus GF fish (Figure 5 – 
figure supplement 1), suggesting that the microbiota increases endocrine progenitor 
proliferation. Whether the microbiota also promote proliferation of mature beta cells in 
the islet and whether BefA promotes the proliferation of one or both of these cell 
populations remains to be determined.  
 To test whether BefA activity was specific to endocrine tissue, or whether it acts 
as a nonspecific pro-proliferative stimulant in the pancreas, we analyzed its ability to 
induce proliferation in exocrine pancreatic tissue by treating Tg(ptf1a:eGFP) larvae 
(Thisse et al., 2004) with EdU and BefA from 4 to 6 dpf and quantifying proliferative 
eGFP positive cells. We found no difference in the level of exocrine cell proliferation 
across GF, CV and BefA treatments (Figure 5C). To test whether beta cells were the only 
endocrine cell type in the islet to be responsive to BefA, we also quantified the total 
number of glucagon-expressing α (Figure 5D) and somatostatin-expressing δ (Figure 5E) 
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cells in GF, CV and BefA treated fish. We again found no difference in the total numbers 
of these cells across treatments (Figure 5F, G). These results suggest that in the pancreas, 
beta cells alone are responsive to the presence of BefA. 
 
Figure 5. BefA facilitates beta cell mass expansion through proliferation. 
(A, D & E) Representative 2D slices from confocal scans through the primary islets of 
GF, CV and BefA (10165) protein treated 6 dpf larvae. Scale bars = 40 µM. (A) Insulin 
promoter expressing beta cells are shown in green, all nuclei are blue, and EdU 
containing nuclei are magenta. Left hand panels are a merge of all three markers. For 
ease of resolving cells that are double positive for both insulin and EdU, the right hand 
panels show location of insulin outlined by white dashed lines. (B) Percentage of EdU 
positive beta cells in CV, GF or GF treated with either purified BefA or CFS from A. 
veroniiΔbefA cultures (ΔbefA CFS). ***p<0.001: Denotes treatment that is significantly 
different than GF by Tukey analysis. (C) Total EdU positive exocrine cells quantified 
from the approximate central longitudinal plane of the pancreas in each fish. (D) Insulin 
promoter expressing beta cells are shown in green, all nuclei are blue, and α cells, stained 
with anti-glucagon antibody are magenta. (E) Somatostatin promoter expressing δ cells 
are shown in white, all nuclei are blue, and beta cells stained with anti-insulin antibody 
are outlined in green. (F) Total α cells in GF, CV and GF fish treated with BefA. (G) 
Total δ cells in GF, CV and GF fish treated with BefA.   
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Figure 5S – figure supplement 1. The microbiota increase beta cell neogenesis from 
the EPD. 
Quantification of EDP localized insulin expressing cells per animal in 6 dpf CV and GF 
larvae. Error bars represent the standard deviation. **t520=3.28, p=0.0011. 
 
 
 
BefA homologs are produced by members of the human gut microbiota and have 
conserved function.  
We wondered if BefA-like proteins are produced by the human microbiota. 
Phylogenetic analysis of related sequences in bacterial genomes uncovered close 
homologs (at least 82% amino acid sequence identity) in many, but not all, species of the 
Aeromonas, Vibrio, and Photobacterium genera. We also found an example of a highly 
related sequence in the human-associated species Enterococcus gallinarum, which was 
likely acquired through a horizontal gene transfer event (Figure 6A). Widening the search 
to include more distant homologs identified potentially related genes in three additional 
human-associated genera: Enterobacter, Escherichia, and Klebsiella (Figure 6B).  
 We tested whether representative BefA-like proteins from human-associated 
bacteria had the capacity to induce beta cell expansion in our gnotobiotic zebrafish 
model. We cloned into BL21 E. coli two befA-like genes: the more closely related 
homologue from Enterococcus gallinarum and a more distantly related homologue from 
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Enterobacter aerogenes. The amino acid sequence alignment of these two homologs 
against the Aeromonas BefA sequence is shown in Figure 6 – figure supplement 1. Both 
the Aeromonas and Enterococcus sequences contain a short N-terminal hydrophobic 
secretion signal, which is not predicted in the more distant Enterobacter sequence. The 
most conserved region of these proteins is the C-terminal portion, which contains a 
putative SYLF domain of unknown function. Induction of expression of each gene in E. 
coli yielded CFS that were dominated by each of the respective homologous proteins, in 
contrast to the CFS from control E. coli expressing an empty vector (Figure 6C). Upon 
addition of these supernatants to GF larval zebrafish, we observed rescue of beta cell 
numbers to the CV level with both the Enterococcus gallinarum and Enterobacter 
aerogenes proteins, but not the empty vector control (Figure 6D, Figure 6 – source data 
1). These results indicate that members of human-associated microbiota produce secreted 
proteins capable of inducing beta cell expansion.  
 
Figure 6. Homologs of BefA encoded in the human microbiome have conserved 
function in zebrafish.  
(A) Close homologs of BefA across microbial species. Each species is represented by its 
closest BefA homolog, with a minimum allowed amino acid sequence identity of 50% 
(relative to the query sequence). Notably, the Enterococcus gallinarum homolog clusters 
among homologs from the Aeromonas genus, which is evidence of a possible lateral gene 
transfer event. (B) A view of the BefA phylogeny including more distant homologs 
(sequence identity >20%) and grouped by genus. The portion of the tree represented in A 
is contained in the light gray box. In both panels, red numbers indicate branch support 
(values closer to 1 are better supported); branches with support values <0.5 have been 
collapsed. Blue clades indicate genera that were associated with humans in metagenomes 
produced during the Human Microbiome Project (HMP). Black arrowheads indicate 
genera tested for functional conservation in panel D. Scale bars indicate amino acid 
substitutions per amino acid site. (C) SDS-page gel: 1 = ladder, 2 = CFS from induction 
of E. coli BL21 carrying an empty vector, 3 = CFS from induction of E. coli BL21 
carrying vector with Enterococcus gallinarum homolog, estimated size of 29 kDa, lane 4 
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= CFS from induction of E. coli BL21 carrying vector with Enterobacter aerogenes 
homolog, estimated size of 21 kDa. White arrows indicate induced proteins. (D) Total 
beta cells in CV, GF and GF fish that have been treated with either induced BL21 E. coli 
supernatant dominated by the homologous BefA protein encoded from Enterococcus 
gallinarum (E. gal. homolog) and Enterobacter aerogenes (E. aero. homolog), or 
induced supernatant from an empty vector control. *p<0.05, **p<0.01, ***p<0.001: 
Denotes treatment that is significantly different than GF by Tukey analysis. 	  
 
 
 
Figure 6S – figure supplement 1. Amino acid sequence alignment of BefA and 
functionally conserved homologs. (next page) 
Amino acid sequence alignment by MUSCLE. Egal = Enterococcus gallinarum homolog 
sequence, Eaero = Enterobacter aerogenes homolog sequence, and BefA = original 
Aeromonas veronii HM21 BefA sequence. Red box contains predicted SYLF domain. 
Blue box indicates predicted secretion peptides. 
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DISCUSSION 
Using a gnotobiotic zebrafish model, we have discovered a class of proteins 
produced by resident gut bacteria that have the capacity to increase expansion of 
pancreatic beta cells during early zebrafish development. BefA and related homologues 
are predicted to contain a C-terminal SYLF domain, which has been described in proteins 
from organisms in all kingdoms of life, including humans, but for which little is known 
functionally beyond a possible role in lipid binding (Hasegawa et al., 2011). Genes 
encoding BefA and related proteins are found in a small subset of all bacteria genera, 
with a predominance in genera of host-associated bacteria, but befA homologues are not 
ubiquitously present in any of these genera.   
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Our finding of a role for specific secreted bacterial proteins in beta cell 
development raises the possibility of a new link between the resident microbiota and 
diseases of beta cell paucity, such as diabetes mellitus. Type 1 diabetes (T1D), is caused 
by both genetic and environmental factors, as indicated by the 50% disease discordance 
among monozygotic twins (Akerblom et al., 2002). One environmental factor associated 
with T1D is microbiota composition (Gülden et al., 2015). Mechanistic models for the 
role of the microbiota in T1D etiology have focused on the capacity of the microbiota to 
modulate the development and function of the immune system, and thus influence the 
propensity of genetically susceptible individuals to develop autoimmunity to beta cell 
antigens (Gülden et al., 2015). Multiple aspects of host immune cell development and 
function known to play a role in T1D are altered by the loss of microbes, including 
development of lymphoid tissue (Macpherson and Harris, 2004) and T cell differentiation 
and function (Alam et al., 2011; Farkas et al., 2015; Ivanov et al., 2008). We hypothesize 
an additional role for the early microbiota in establishing the beta cell population size that 
would either buffer against, or render individuals susceptible to, beta cell depletion by 
autoimmune destruction.  
In humans, beta cells undergo a period of postnatal expansion, before becoming 
quiescent around age two (Gregg et al., 2012). Differences in beta cell growth during this 
time are thought to account for the wide variation in beta cell mass observed in adults 
(Wang et al., 2015). The idea that early life beta cell census could influence diabetes risk 
is supported by studies in both rodents and humans, and has been theorized as an 
important risk factor for type 2 diabetes (Kaijser et al., 2009), a disease which is also 
influenced strongly by microbiota composition (Cox and Blaser, 2014). Compromised 
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beta cell development in rats results in an insufficient number of cells to adequately 
control glucose metabolism (Figliuzzi et al., 2010). In mice, perinatal beta cell 
proliferation rates can be tuned via the modulation of Gi-GPCR signaling (Berger et al., 
2015). Changes to early beta cell proliferation capacity in these mice correlates directly 
with adult beta cell mass, which subsequently impacts glucose regulation (Berger et al., 
2015). Furthermore, meta analysis of human data has revealed a correlation between 
early age of beta cell loss and more rapid onset of T1D (Klinke, 2008), consistent with 
the model that failure to generate a reserve of beta cells early in development increases 
disease risk. 
We hypothesize that neonatal microbiomes with a low abundance of BefA 
equivalents would result in reduced beta cell proliferation, lower beta cell mass, and 
increased diabetes risk. We do not know how many different microbiota-derived 
molecules can stimulate beta cell proliferation, but for the case of befA homologues, we 
know these to be sparsely distributed in bacterial genomes, such that microbiomes of low 
taxonomic diversity could lack these genes. The idea that microbiota-derived factors 
capable of protecting against diabetes are not widely conserved is consistent with human 
microbiota profiling data (Morgan et al., 2013), our own functional assays of bacteria in 
gnotobiotic zebrafish, and other gnotobiotic rodent experiments. For example, specific 
bacterial lineages have been shown to attenuate disease in diabetes models, including 
Segmented Filamentous Bacteria (SFB) in the non-obese diabetic (NOD) mouse (Kriegel 
et al., 2011; Yurkovetskiy et al., 2013) and Lactobacillus johnsonii in the Biobreeding rat 
model (Valladares et al., 2010). Furthermore, Wen and colleagues have shown that 
certain microbial assemblages, but not others, confer disease protection in neonatal NOD 
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mice (Peng et al., 2014). Additional recent work by Wen and colleagues demonstrates 
early development as a critical window for microbiota modulation of disease risk in NOD 
mice (Hu et al., 2015). We have shown that BefA acts during early developmental stages 
in zebrafish, and we hypothesize that beta cell expansion during this developmental 
window is important for disease prevention, and may be a critical period for clinical 
intervention for infants at risk for T1D development. Further work will be required to 
determine whether BefA is capable of inducing proliferation of adult beta cells in 
zebrafish or other animals. 
 Why certain bacteria produce BefA is unclear. In the context of the zebrafish 
intestinal environment, BefA confers a slight colonization advantage to A. veronii, 
however this is unlikely to be related to its capacity to induce beta cell mass, because the 
colonization requirement is only apparent in the context of co-colonization with wild type 
A. veronii that induce normal beta cell numbers. It is possible that bacterial modulation of 
host beta cell number serves a purpose for the bacteria not measured in our assay. 
Alternatively, bacteria may produce BefA for a purpose independent of beta cell 
expansion and the host simply uses this bacterial molecule as a cue for its own 
developmental program. Learning the molecular basis for BefA sensing by the host, and 
whether it interacts directly or indirectly with beta cells, will help shed light on the nature 
and evolutionary conservation of this interspecies signaling. It will also be important to 
understand the bacterial function of BefA in order to be able to manipulate its abundance 
for potential therapeutic purposes. 
The incidence of autoimmune diseases such as T1D has been increasing markedly 
in developed nations over the past several decades. One theory to explain this 
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phenomenon is the disappearing microbiota hypothesis, which proposes that over time, as 
our modern lifestyles have become increasingly sterile, we have lost ancestral microbial 
symbionts important for specific aspects of our health (Blaser and Falkow, 2009). Our 
discovery of a specific class of bacterial proteins that promote beta cell expansion in early 
development is consistent with the hypothesis that loss of specific microbial taxa from 
gut microbiota could underlie increased diabetes risk. Specifically, we suggest that BefA-
like proteins promote the establishment of a robust beta cell population that is more 
resilient to subsequent beta cell loss. Because befA is a relatively rare component of the 
microbiome, we cannot measure it directly from available metagenomic sequence data to 
test our hypothesis that befA abundance correlates with reduced diabetes risk. The low 
abundance of befA in metagenomes also highlights the challenge of discovering disease 
determinants from metagenomic data, and emphasizes the importance of functional 
screening approaches. The larval zebrafish has served as a valuable high-throughput 
vertebrate model for the identification of new compounds and pathways that can increase 
beta cell numbers exogenously (Andersson et al., 2012; Wang et al., 2015). We have 
employed the gnotobiotic zebrafish to explore how microbial cues modulate beta cell 
development. Our discovery of BefA highlights the importance of the microbiota in 
shaping the development of an extra-intestinal tissue and influencing the overall 
metabolic state of the host. We postulate that resident bacteria are a rich and 
underexplored source of functionally conserved molecules that shape early host 
development in ways that impact disease risk in later life. 
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MATERIALS AND METHODS 
Gnotobiotic zebrafish 
All zebrafish experiments were performed using protocols approved by the 
University of Oregon Institutional Care and Use Committee and followed standard 
protocols. Zebrafish embryos were derived germ-free (GF) as previously described 
(Bates et al., 2006). XGF and mono-associated larvae were also generated as previously 
described (Bates et al., 2006), except that all bacterial inoculate were added to GF flasks 
at 4 dpf at a final concentration of 106 CFUs/mL. In experiments quantifying the 
colonization levels of bacterial isolates, each strain was added to the embryo media (EM) 
and incubated with the larvae for 48 hours at 27° C. Larvae were sacrificed at 6 dpf, 
immediately before the gut was removed and homogenized in a small sample of sterile 
EM. Dilutions of this gut slurry were plated onto tryptic soy agar and allowed to incubate 
overnight at 30° C. Colonies from each gut were quantified. A minimum of 10 guts per 
mono-association or di-association were analyzed.  
 
Free Glucose Assay 
To measure beta cell function in GF and CV zebrafish larvae, levels of free 
glucose were measured at 6 dpf using a free glucose assay kit (BioVision, Milpitas, CA) 
as described previously (Andersson et al., 2012; Gut et al., 2013) except that only 10 
larvae were combined per tube. Three to five biological replicates (sets of 10 larvae) were 
completed for both GF and CV treatments each time the assay was conducted. Data 
shown here were combined from 3 separate experimental assays or technical replicates. 
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Cell Free Supernatant 
GF fish were inoculated with secreted bacterial products at 4 dpf by adding cell 
free supernatant (CFS) at a final concentration of 500 ng/mL to the water of the sterile 
flasks. CFS was harvested from a 50 mL overnight culture of the specified bacterial 
strain. The cultures were centrifuged at 7000 g for 10 minutes at 4° C. The supernatant 
was then filtered through a 0.22-µm sterile tube top filter (Corning Inc., Corning, NY); 
sterile supernatant was concentrated at 4° C for 1 hour at 3000 g with a centrifugal device 
that has a 10 kda weight cut off (Pall Life Sciences, Port Washington, NY).  
 For experiments utilizing proteinase K (Qiagen, Hilden, Germany), the enzyme 
was added to samples of CFS at a final concentration of 100 µg/mL and allowed to 
incubate at 55° C for 1 hour before inactivating the enzyme at 90° C for 10 minutes. 
 
Ammonium Sulfate Fractionation 
Ammonium sulfate fractionation was performed on un-concentrated, sterile CFS 
from a 50 mL overnight culture by slowly adding 100% ammonium sulfate until 
solutions of 20%, 40%, 60% and 80% ammonium sulfate were achieved. These solutions 
were prepared at 4° C. Precipitated proteins were collected from each fraction by 
centrifugation at 4° C and 14000 g for 15 minutes. The proteins were resuspended in cold 
EM and dialyzed for 2-3 hours at 4° C before adding them to 4 dpf GF larvae at a final 
concentration of 500 ng/mL. 
 
Mass Spectrometry 
 The 60-80% ammonium sulfate fraction of the A. veroniiΔT2SS CFS was sent to the 
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Proteomics Lab at Oregon Health and Science University in Portland, OR for protein 
identification (partial sequencing) analysis.  
 
Protein expression and purification 
The nucleotide sequence for the befA gene from was amplified from A. veronii 
using the following forward and reverse PCR primers respectively: 5’-
GCCCATATGatgaacaagcgtaactggttgctg-3’ and 5’-GGCCTCGAGgcggctcgtttcagtcaagtc-
3’. The nucleotide sequences for both the Enterococcus gallinarum and Enterobacter 
aerogenes befA gene homologs were obtained from NCBI and subsequently synthesized 
by GenScript, Piscataway, NJ. Each of these two genes was then cloned separately into 
the pET-21b plasmid (Novagen, Darmstadt, Germany), which contains an IPTG 
inducible promoter. A His Tag® was added to the C-terminal of the original BefA 
protein sequence for subsequent purification. As a control, a second version was also 
constructed lacking the tag. These vectors were then transformed into BL21 Escheria coli 
(RRID:WB_HT115(DE3)), treated with 0.5 – 1.0 mM IPTG during exponential growth 
phase (OD600 = 0.4 - 0.6) and allowed to grow for 3-4 more hours at 30° C. This resulted 
in both a CFS and cell lysate dominated by our proteins of interest, as confirmed via 
SDS-page gel electrophoresis by the presence of dark bands of the expected sizes for 
each protein. These bands were absent from BL21 cultures carrying an empty pET-21b 
vector. The CFS from these inductions was added to GF zebrafish at 4 dpf at a final 
concentration of 500 ng/mL. 
For purification of BefA, IPTG induced BL21 cells were sonicated at 32,000 g in 
a 50 nM Tris, 150 mM NaCl buffer (buffer A). The supernatant was then added to a 
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solution of nickel beads (Thermo Scientific HisPurTM Ni-NTA Resin, Waltham, MA) to 
capture the His tag. The beads were washed several times in a 30 mM imidazol solution 
in buffer A and subsequently eluted in 300 mM imidazole solution in buffer A. The 
isolation of pure BefA was confirmed with SDS-page gel electrophoresis by the presence 
of a single band of about 29 kDa in size. Purified BefA was added to 4 dpf GF fish at a 
final concentration of 500 ng/mL.  
  
Experimental bacterial strains  
To create the A. veroniiΔbefA mutant strain, a vector containing a chloramphenicol 
resistance cassette was transformed into SM10 E. coli. Conjugation between wild-type 
Aeromonas veronii HM21 and the vector carrying SM10 E. coli strain was carried out, 
allowing the chloramphenicol resistance gene to replace the befA locus in A. veronii via 
allelic exchange. Candidate mutants were selected for loss of the plasmid and 
maintenance of chloramphenicol resistance. Insertion of the chloramphenicol cassette 
into the befA locus was verified in these candidates by PCR.  
 Joerg Graf graciously provided us with the A. veroniiΔT2SS strain (Maltz and Graf, 
2011).  
  
Primary islet cell type quantifications and EdU staining in larvae 
Tg(-1.0insulin:eGFP) (RRID:ZFIN_ZDB-GENO-100513-10, ZIRC, Eugene, OR)  
(diIorio et al., 2002) zebrafish embryos were used to visualize and quantify the total 
number of beta cells in developing larvae. Tg(insulin:PhiYFP-2a-nsfB, sst2:mCherry) 
(RRID:ZFIN_ZDB-GENO-120217-6) (Wang et al., 2015) were obtained from Jeff 
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Mumm and were used to visualize and quantify δ cells. All experiments were analyzed at 
6 dpf unless otherwise specified. At all time points in all experiments, larvae were fixed 
with 4% paraformaldehyde supplemented with 0.01% Triton® X-100 (Thermo Fisher 
Scientific, Waltham, MA) at 4° C overnight, or at room temperature for 2-3 hours, and 
then washed with PBS. The following antibodies were used to distinguish α and beta 
cells: guinea-pig anti-insulin (Dako Cat# A0564, RRID:AB_10013624 , Carpinteria, 
CA), mouse anti-glucagon (Sigma-Aldrich Cat# G2654, RRID:AB_259852), St. Louis, 
MO), rabbit anti-GFP (Molecular Probes Cat# A-11122, RRID:AB_221569), mouse anti-
mCherry (Abcam Cat# ab125096, RRID:AB_11133266, Cambridge, MA), Alexa Fluor® 
488 goat anti-rabbit (Thermo Fisher Scientific, Waltham, MA), anti-mouse Cy3 (Jackson 
ImmunoResearch Laboratories Inc., West Grove ,PA), Alexa Fluor® 488 goat anti-
guinea-pig (Thermo Fisher Scientific, Waltham, MA), and TO-PRO®-3-Iodide (642/661) 
(Thermo Fisher Scientific, Waltham, MA).  
For experiments quantifying proliferation, EdU was added at 4 dpf directly to the 
EM at a final concentration of 0.1 mg/mL. The Click-iT® EdU Imaging Kit (Thermo 
Fisher Scientific, Waltham, MA) was used to process the EdU label in whole fixed 
zebrafish prior to antibody staining, according to the manufacturer’s protocols. Whole, 
antibody-stained larvae were mounted for confocal microscopy (BioRad Radiance 2100) 
with their right side facing up against the cover slip, which was flattened sufficiently to 
spread our the cells within the islet for optimal quantification of individual cells. For 
quantification of beta cells and other primary islet cells, the entire endocrine portion of 
the pancreas was scanned using a 60X objective (Nikon Eclipse E600FN), and Fiji 
(RRID:SCR_002285) (Schindelin et al., 2012) software was used to analyze each image 
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stack. For quantification of pancreatic exocrine tissue proliferation, Tg(ptf1a:eGFP) 
(RRID:ZFIN_ZDB-GENO-080111-1, ZIRC, Eugene, OR) (Thisse et al., 2004) zebrafish 
were scanned through the entire pancreas with a 20X objective (Nikon Eclipse E600FN) 
and Fiji was used to analyze the percentage of proliferative cells in single sections from 
the center of the organ. Images were prepared for publication using the open source 
Inkscape software (RRID:SCR_014479).  
For experiments quantifying insulin-expressing cells in the region of the EPD, 
zebrafish were processed as described above, and analyzed on a Leica fluorescent 
microscope using a 2x objective.  
 
BefA phylogenetic analysis 
We screened for BefA homologs across microbial species using a blastp-based 
(Altschul et al., 1997) search of the UniProt Knowledgebase (The UniProt Consortium, 
2015) (version 6/2015); default search parameters were changed to allow (i) a maximum 
E-value of 1.0 and (ii) an arbitrarily large number of database hits. We classified database 
hits as “close homologs” if amino acid sequence identity exceeded 50% (relative to the 
query length) and “distant homologs” if their percent identity exceeded 20%. For 
phylogenetic analysis at the species level, each species was represented by the hit of 
highest percent identity to BefA among isolates of that species (if any); an analogous 
procedure was used for genus-level analysis. Aligned portions of database sequences 
were isolated and multiply aligned with MUSCLE (RRID:SCR_011812) (Edgar, 2004). 
Phylogenetic trees were constructed from these multiple sequence alignments using 
PhyML (RRID:SCR_014629) (Guindon and Gascuel, 2003) and visualized within the 
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Phylogeny.fr webserver (Dereeper et al., 2008). Microbial genera were classified as 
“human-associated” if they occurred with relative abundance >0.01% in at least 5 
metagenomes from the Human Microbiome Project (Huttenhower et al., 2012) as profiled 
by MetaPhlAn (RRID:SCR_004915) (Segata et al., 2012). Secretion signal peptides were 
predicted from amino acid sequences using SignalP (Petersen et al., 2011). 
 
Statistical Analysis 
Appropriate sample sizes for all experiments were estimated a priori using a 
power of 80% and a significance level of 0.05. From preliminary experiments we 
estimated variance and effect. For larval beta cell quantification, these parameters 
suggested using a sample size of 30 in order to detect significant changes between 
treatment groups. Therefore, each experiment contained about 10-15 biological replicates 
or individual fish per treatment group, although some larger experiments had fewer 
biological replicates due to limited material. Entire experiments or technical replicates 
were repeated multiple times, resulting in pooled data sets of about 20-50 biological 
replicates. These data are represented in the figures as box and whisker plots, which 
display the data median (line within the box), first and third quartiles (top and bottom of 
the box), and 95% confidence interval (whiskers). Any data point falling outside the 95% 
confidence interval is represented as a solid dot. These pooled data were analyzed 
through the statistical software RStudio®. For experiments comparing just two 
differentially treated populations, a Student’s t-test with equal variance assumptions was 
used. For experiments measuring a single variable with multiple treatment groups, a 
single factor ANOVA with post hoc means testing (Tukey) was utilized. A p-value of 
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less than 0.05 was required to reject the null hypothesis that no difference existed 
between groups of data. 
 
BRIDGE  
In Chapter II, we showed that the bacterial protein BefA, is sufficient to induce 
zebrafish pancreatic beta cell expansion, and that members of both the zebrafish and 
human intestinal microbiota produce and secrete BefA into the host environment. 
However, we do not yet know how the host senses and responds to this protein. To 
further our understanding, in the next chapter we present the atomic structure of BefA, 
which represents a new protein fold that includes the first structural description of an 
SYLF domain, which is the most conserved region of the protein amongst homologs. We 
show that the SYLF domain is sufficient to induce larval beta cell expansion in GF 
zebrafish larvae. Using zebrafish islet explants, we present evidence to support the 
hypothesis that this effect is mediated through a direct interaction between the SYLF 
domain and pancreatic cells, suggesting that BefA acts directly on the pancreas, possibly 
transported to this tissue from the gut lumen.  
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CHAPTER III 
THE ATOMIC STRUCTURE OF BEFA REVEALS A NEW PROTEIN 
FOLD SUFFICIENT FOR BETA CELL EXPANSION 
The procedures involved in solving the BefA crystal structure described in this chapter 
were completed thanks to large contributions from Dr. Emily Sweeney, who helped to 
derive selenium methionine substituted BefA, to solve the x-ray diffraction pattern of the 
resulting crystals, and to design truncation constructs, Dr. S. James Remington who 
solved the crystal structure of BefA, and Karen Kallio, who guided me in the protocol to 
find appropriate crystallization conditions for BefA. 
  
INTRODUCTION 
Beta cell expansion factor A (BefA) is a small 29 kDa protein produced by some 
members of the intestinal microbiota of various hosts including zebrafish and humans 
(Hill et al., 2016). Recently, we showed that the microbiota is required for zebrafish beta 
cell expansion during the larval period after the animals hatch from their chorions and 
first become colonized by environmental microbes. We discovered BefA in a screen for 
bacterial products that could rescue germ free (GF) larval beta cell development. Because 
mechanisms of beta cell renewal are sought after as potential treatments for diabetes, we 
became interested in whether or not human associated bacteria produce BefA or similar 
proteins. Upon searching metagenomic databases from the Human Microbiome Project, 
we found several species that had genes encoding predicted homologs of BefA. Notably, 
these genes were not common across any bacterial genus, but seemed to be present in a 
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small handful of strains or species. We examined two of these homologs, one with only 
34% amino acid sequence similarity to BefA, and found that they were both sufficient to 
rescue GF larval beta cell development.  
 To begin to understand how these proteins could induce this effect, we used 
amino acid alignments and found that the C-terminus was the most conserved region 
across BefA homologs. This conserved region is relatively large compared to the size of 
BefA, encompassing roughly two thirds of the entire amino acid sequence, and is 
predicted to encode a SYLF/YAB domain, also called DUF (domain of unknown 
function) 500. Interestingly, some of the homologs of BefA are smaller proteins and this 
predicted domain constitutes their entire amino acid sequence. Little is known about 
these protein domains, despite their prevalence across the kingdoms of life, from bacteria 
to fungi and animals (Hasegawa et al., 2011). However, their role in two distinct proteins, 
one found in yeast and the other in mammals, has been investigated, providing hints 
about their biological functions (Hasegawa et al., 2011; Robertson et al., 2009; Tonikian 
et al., 2009). 
The YAB domain was described first in 2009 in the yeast protein Ysc84, and is 
named after its observed function for Ysc84 actin binding (Robertson et al., 2009). The 
YAB domain is located at the N-terminus of Ysc84 and is attached by a linker to a SH3 
domain in the C-terminus (Robertson et al., 2009). Robertson et al. showed that the YAB 
domain of Ysc84 is sufficient to bind to F-actin, a function necessary for its role in 
endocytosis. In 2011, Hasegawa and colleagues described a homolog of the YAB domain 
in the mammalian SH3YL1 protein, and they re-named the region SYLF, after each of 
the proteins known to contain it at that time (SH3YL1, Ysc84p/Lsb4p, Lsb3p, and 
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FYVE). SH3YL1 was first discovered in mice, and is widely expressed in many organ 
systems (Urbanek et al., 2015). Like Ysc84, the SYLF domain of SH3YL1 is also located 
in the N-terminus with an attached C- terminus SH3 domain (Hasegawa et al., 2011). 
However, the SYLF domain of SH3YL1 can’t bind to F-actin (Hasegawa et al., 2011). 
Instead it interacts with D5-phosphoinositides and has a role in regulating membrane 
ruffle formation (Hasegawa et al., 2011). Plant proteins containing a C-terminus SYLF 
domain attached to an N-terminus FYVE domain can be found in the genomes of 
Arabidopsis thaliana and Oryza sativa, however their specific SYLF domain functions 
have not been studied (Urbanek et al., 2015). Similar to the mammalian SH3YL1 SYLF 
domain, FYVE domains in Arabidopsis sp. are known to interact with 
phosphatidylinositol-3-phosphate at the plasma membrane, and generally play a role in 
endocytosis and/or vesicular trafficking (Wywial and Singh, 2010). Although research on 
SYLF/YAB domains is limited, it seems that an emerging theme surrounding the role of 
this newly discovered domain is the organization of protein interactions to carry out 
cellular functions at the plasma membrane. So far our description of BefA is the only 
insight into the function of a bacterial SYLF/YAB domain containing protein (Hill et al., 
2016). Here we attempt to better understand the role of the SYLF domain in the function 
of BefA in host physiology.  
 Toward this goal, we have solved the crystal structure of BefA. This new protein 
structure not only exhibits a novel-folding pattern, it also provides the first known 
structure for any SYLF domain, which will be helpful in furthering our understanding of 
this widely distributed protein domain’s function. We also present evidence that the 
SYLF domain of BefA is required for its ability to induce host beta cell proliferation, and 
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that this effect is mediated through direct interactions between the SYLF domain and 
pancreatic cells. This observation raises the question of whether or not the SYLF domain 
of BefA, like other described SYLF/YAB domains, is important for organizing 
interactions at the cell membrane. Importantly, our data provide a new understanding of 
how microbial products can impact host cell biology.  
 
RESULTS 
The structure of BefA reveals a novel protein fold containing a SYLF domain 
 To better understand how BefA functions, we set out to determine its 3D atomic 
structure.  Purified BefA protein crystallized readily and the structure was determined to 
1.6 Å resolution using a selenomethionine derivative and single-wavelength anomalous 
dispersion (SAD) phasing. The atomic resolution structure revealed a compact partial 
beta-barrel carboxy-terminal domain with three flanking α-helices and four loosely 
packed α-helices in the amino terminal region (Figure 3.1A&B). From sequence 
comparison and analysis using the Conserved Domain Databank (Marchler-Bauer et al., 
2017), we conclude that BefA contains a SYLF domain. Surprisingly, the BefA structure 
does not have homology to any structures deposited in the Protein Data Bank (PDB), 
using PDBeFold (Krissinel and Henrick, 2004, 2005), indicating that we have determined 
a novel protein fold. 
  To better define the structural features that constitute a functional SYLF domain, 
we performed a detailed structural comparison between the Aeromonas veronii BefA and 
a distant BefA homolog identified in Enterobacter aerogenes. Although the two 
sequences have only 34% identity, the E. aerogenes homolog is fully functional in 
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increasing beta cell numbers in larval zebrafish (Hill et al., 2016). We obtained a model 
structure of E. aerogenes using the Iterative Threading ASSEmbly Refinement (I-
TASSER) server and BefA as a template (Roy et al., 2010; Yang et al., 2014; Zhang, 
2008). Overlaying the structure of BefA and the model of the BefA homolog (Figure 
3.1B, black) revealed that the two amino terminal α-helices (H1, H2) are dispensable for 
function (Figure 3.1B). We therefore have putatively defined the functional SYLF 
domain to be a curved beta-sheet containing seven antiparallel beta-strands interspersed 
with five α-helices (Figure 3.1B).  
 
Figure 3.1. The structure of BefA reveals a novel protein fold containing a SYLF 
domain 
(A) Cartoon ribbon structure of BefA, N and C designate the amine and carboxyl 
terminus respectively. (B) BefA ribbon structure in green, overlaid with predicted 
structure for the BefA homolog produced by E. aerogenes in black, H1-H4 label N-
terminus alpha helices 1-4, predicted SYLF domain is roughly between black brackets. 
 
 
 
One of the best-characterized behaviors of SYLF domains is lipid binding 
(Urbanek et al., 2015). Preliminary work to determine if BefA binds lipids has been 
inconclusive. Lipid binding strip assays revealed specific binding to phosphatidylserine 
(PS) and cardiolipin. However, subsequent lipid binding assays using more 
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physiologically relevant lipid bilayers, including tryptophan fluorescence, vesicle 
pelleting and molecular dynamic simulations, have shown little to no binding to 
phosphatidylserine (PS), despite success using annexin V, which binds stongly to PS, as a 
positive control (data not shown). More thorough lipid binding characterization is 
required to determine whether BefA binds lipids in vivo and whether BefA’s pro-
proliferative molecular mechanism involves lipid membrane or vesicle binding.  
Because we have evidence that BefA may interact with PS, which is most known 
for its role in apoptosis, we performed Tunnel staining for apoptotic cells on 6 dpf larvae 
that were either GF, CV or GF treated with BefA. We did not detect any Tunnel positive 
beta cells within any of the samples (data not shown), indicating that apoptosis does not 
normally occur in developing larval beta cells and suggesting that BefA does not 
modulate apoptotic signaling to regulate the beta cell population.  
 
The SYLF domain of BefA is sufficient to rescue normal expansion of the GF beta cell 
mass 
We cloned two truncated BefA proteins to determine which region of BefA was 
necessary and sufficient to mediate the pro-proliferative effect on larval beta cells. One 
truncation comprised amino acid numbers 99 – 261, which encode the entire predicted C 
terminal SYLF region (BefA99) (Figure 3.1B, Figure 3.2A). The second shorter 
truncation incorporated only amino acids 133-261, which corresponds to the C terminus 
compact partial beta-barrel with the small flanking α-helices (BefA133) (Figure 3.2A). We 
tested each purified truncated BefA protein, in comparison to the full length BefA, on 4 
dpf GF larvae by adding them to the water at a final concentration of 500 ng/mL. By 6 
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dpf, following 48 hours of treatment, BefA99 was equally effective at rescuing GF beta 
cell expansion as full length BefA, suggesting that the SYLF domain is sufficient to 
induce larval beta cell proliferation (Figure 3.2B). BefA133 was only able to partially 
rescue GF beta cell numbers (Figure 3.2B). Confocal images of the center of the primary 
zebrafish islet show many more GFP-expressing cells in fish treated with either full 
length BefA or BefA99 than in GF counterparts (Figure 3.2C). The BefA133 treated islets 
often appear similar to GF (Figure 3.2C), however they sometimes had more robust beta 
cell numbers approaching levels within CV fish (data not shown). These data suggest that 
the two most N terminal alpha helices (H1 & H2) are dispensable for the full function of 
BefA and that both H3 and H4, or important residues therein, are required for complete 
function.  
 
Figure 3.2. The SYLF domain of BefA is sufficient to rescue normal expansion of the 
GF beta cell mass (next page) 
(A) Left are cartoon representations of the structures predicted to result from the 
corresponding truncation scheme illustrated on the right, each amino acid sequence is 
represented by a green rectangle with numbers beneath corresponding to the amino acid 
number on BefA where the truncation begins. (B) Quantification of total beta cells per 
fish, in these and all subsequent box plots the whiskers denote the 95% confidence 
interval of the data and lowercase letters denote results of post host means testing where 
p<0.05. (C) Representative 2D slices from confocal scans through the primary islets of 6 
dpf CV and GF Tg(-1.0insulin:eGFP) larvae. Each slice is taken from the approximate 
center of the islet structure. Insulin promoter expressing beta cells are in green and nuclei 
are white. Scale bar = 40µM. 
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BefA increases beta cell number of GF ex vivo larval zebrafish islets 
A critical question about BefA’s mechanism of action is whether it acts directly 
on pancreatic cells or alternatively via an indirect route such as eliciting expression of a 
secondary messenger in intestinal cells. To test whether BefA could act directly on 
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pancreatic cells, we dissected pancreatic heads containing the primary islet from GF 4 dpf 
Tg(-1.0insulin:eGFP) larvae (Figure 3.3A) and maintained them ex vivo in culture for 48 
hours untreated or in the presence of either BefA or BefA99. Ex vivo larval beta cells 
appeared healthy after 48 hours as indicated by robust insulin promoter driven gfp 
transgene expression, and an otherwise normal appearance. After the treatment period, 
we immediately imaged and quantified total GFP expressing cells in each islet in each 
treatment and saw significantly more beta cells in explants treated with BefA or BefA99 
than in those that received only rich cell culture media (Figure 3.3B), suggesting that 
BefA elicits beta cells expansion through a direct interaction with pancreatic cells and 
that the SYLF domain of BefA is sufficient for this activity. From these data, we can not 
distinguish between a direct interaction between BefA and the beta cells in the explants 
or an interaction between BefA an some other cell type in the explants, such as other 
endocrine cells, cells in the pancreatic ductal system, or exocrine cells, that produces a 
signal to elicit proliferation of beta cells. 
 
Figure 3.3. BefA increases beta cell number of GF ex vivo larval zebrafish islets 
(A) Cartoon depicting dissection of pancreas head from a 4 dpf Tg(-1.0insulin:eGFP) 
larvae, gut in white, pancreas in grey, primary islet in green, dashed red line = cut site. 
(B) Quantification of total beta cells per dissected pancreatic head.  
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DISCUSSION 
 Solving the crystal structure of BefA revealed a novel protein fold, which 
includes the first description of an SYLF/YAB domain. The fold is comprised of a series 
of four alpha helices followed by seven beta strands, which form a curved beta sheet in 
the C terminus of the BefA protein. Based on our mutational analysis of the functional 
domain of the A. veronii BefA and comparisons with the smaller functional E. aerogenes 
homologue, we propose that a functional SYLF domain constitutes the third and fourth 
N-terminal alpha helices and the curved beta sheet. This atomic structure of the SYLF 
domain is consistent with previous predictions about the SH3YL1 SYLF domain 
structure. Hasegawa and colleagues predicted a N-terminal alpha helix in the SYLF 
domain, and showed that loss of this region corresponded to loss of lipid binding, 
suggesting the amphipathic region within this helix is necessary to mediate lipid binding 
in SH3YL1 (Hasegawa et al., 2011). Similarly, we found partial loss of function with the 
BefA133 truncation mutant, which had no N-terminal alpha helices, suggesting that in our 
model, one or both of these helices may also be important for function. However, more 
work will be required to determine whether lipid binding or actin binding by this region 
is involved. Importantly, in both yeast Ysc84 and mammalian SH3YL1, their functions at 
the membrane are dependent upon the C-terminal SH3 domain (Urbanek et al., 2015). 
Likewise, in plants, SYLF domains are attached to a second functional domain with 
membrane lipid binding capabilities (Hasegawa et al., 2011; Wywial and Singh, 2010). In 
BefA and other bacterial homologs, the SYLF domain comprises the majority of the 
protein and is not attached to other functional regions making predictions about its 
mechanism in host beta cells difficult. Further work to identify potential binding partners 
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of BefA, will hopefully shed more light on how it elicits beta cell proliferation. 
Furthermore, this information would be valuable in learning more about the function 
BefA provides to bacteria. 
 We also showed evidence that a direct interaction between the SYLF domain of 
BefA and pancreatic cells results in larval beta cell mass expansion. This observation 
raises many interesting questions about the dynamics of BefA’s transport from the gut 
lumen to the pancreas. For instance, maintaining the integrity of the intestinal barrier 
between bacteria within the lumen and the host cells is important to maintain host health 
and to control inflammation (Natividad and Verdu, 2013). Breaches of this barrier, by 
both bacteria and their products, are often associated with disease or pathogen infections 
(Mu et al., 2017). However, BefA is a bacterial product that promotes host development 
and healthy glucose homeostasis so we must begin to consider how the host controls and 
interprets microbial factors that cross this barrier. Additionally, once out of the gut 
lumen, there are multiple physical pathways that BefA could use to reach its systemic 
target. In general, physical travel from the gut to the pancreas involves a relatively great 
distance, across a range of conditions. The fact that BefA is able to interact directly with 
the distant pancreatic cells, suggests that it can withstand these environmental stresses, 
although we have no idea whether it diffuses across these landscapes or is actively 
transported and protected by a host mechanism. One scenario is that epithelial or immune 
cells take up BefA from the gut lumen and subsequently deposit it into the blood stream 
where it would be shuttled directly to the highly vascularized pancreatic cells via the 
hepatic portal vein. Alternatively, the extra pancreatic duct provides a direct luminal 
pathway from the gut to the pancreas. However, we have not ruled out the possibility that 
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BefA is also able to utilize indirect signaling mechanisms to act systemically. Future 
work is required to fully understand the biologically relevant manner in which BefA 
mediates beta cell proliferation. Nevertheless, the possibility that BefA and beta cells 
directly interact holds promise for its use in promoting in vitro expansion of beta cell 
tissue. This is an important step for treatments utilizing both human donor tissue and 
stem cell derived material for transplantation as a method to treat diabetes(Balamurugan 
et al., 2012).  
 Novel protein folding patterns have not been described in several years. Our 
discovery of BefA’s structure suggests that host-associated bacterial genomes are an 
untapped source of protein structural novelty. Further investigation into the biochemical 
properties of these molecules could help to expand our knowledge of protein functions 
and their potential uses for human wellbeing. 
 
MATERIALS AND METHODS 
Protein expression & purification  
The befA gene was expressed and purified as previously described (Hill et al. 
2016). Additionally, BefA protein containing selenium methionine was produced as 
described by Van Duyne et al, and purified using the same methods as native BefA (Hill 
et al. 2016). The nucleotide sequences corresponding to the Befa99 and BefA133 
truncations were amplified using the same reverse PCR primer previously published for 
amplifying BefA (), which was paired with the following forward PCR primers for each 
truncation respectively: 5’-GGCCATATGATGaagacggcgaaagaggcgagg-3’ and 5’-
GGCCATATGATGggttatgcggtgttcgattcgcgc-3’. Each construct was cloned into the pET-
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21b plasmid (Novagen, Darmstadt, Germany) and expressed and purified using a C 
terminal His Tag® as previously described for the native BefA protein (Hill et al. 2016).      
  
BefA crystallization and structure determination 
Purified BefA and selenium methionine substituted BefA (semetBefA) were 
crystalized from a starting concentration of 10-16 mg/mL in a reservoir solution of: 24-
25% PEG 3350 (Hampton Biologicals), 0.1M citric acid pH 3.5, and for semetBefA, 
1mM TCEP. Hanging drop vapor diffusion with ratios of protein to reservoir solution of 
either 1:1 or 2:1, resulted in crystals within 7-10 days. Crystals were cryoprotected in the 
reservoir solution plus 20% PEG 200 (Hampton Biologicals). Crystals were flash frozen 
in liquid nitrogen for data collection at the Advanced Light Source in Berkeley, CA 
beamline 5.0.2 using the Pilatus detector.  
 
Gnotobiotic zebrafish 
All zebrafish experiments were performed using protocols approved by the 
University of Oregon Institutional Care and Use Committee and followed standard 
protocols. Zebrafish embryos were derived GF as previously described (Bates et al., 
2006).  For experiments involving the treatment of larvae with purified protein, the 
protein was added directly to the embryo media at a final concentration of 500 ng/mL.  
Tg(-1.0insulin:eGFP) larvae were incubated with proteins from 4-6 dpf and beta cell 
mass was determined as previously described (Hill et al., 2016).  
 
Zebrafish primary islet dissection and treatment 
  
 
57 
Gut dissections were performed on 4 dpf Tg(-1.0insulin:eGFP) larval zebrafish as 
previously described (Bates et al., 2006). Since the pancreas is tightly associated with the 
gut, it came along readily with dissected gut tissue. The top portion of the gut bulb, and 
the head of the pancreas just below the islet, was dissected away from the rest of the 
gastronitestinal organs, so all that remained was the primary islet and a small amount of 
surrounding tissue, which varied in make-up between dissections, but likely included 
some amounts of exocrine pancreas, duct, and intestine. We found that leaving this small 
amount of supporting tissue was necessary to keep the islet in tact for accurate beta cell 
quantification. Each dissection was transferred into a sterile PCR tube containing 50 uL 
of Leibovitz’s L15 Media with GlutaMax Supplement (Thermo Fischer) supplemented 
with 100 µg/mL penn/strep. Protein treatments were added at a final concentration of 500 
ng/mL and allowed to incubate at RT for 48 hours. Following treatment, single islets 
were mounted directly onto a slide with 5 uL of Prolong with DAPI (Molecular Probes) 
and a coverslip. Each islet was imaged immediately after mounting on an Olympus 
confocal microscope and then analyzed as previously described. 
 
Statistical Analysis 
Statistical analysis for beta cell mass determination was conducted in the same manner as 
was described previously (Hill et al., 2016). 
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CHAPTER IV 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
 Using the zebrafish model system, we have described a new role for the 
microbiota in pancreatic development. By taking advantage of the natural and 
coincidental timelines of larval pancreas development and initial microbial colonization, 
we were able to observe and characterize this process. Upon hatching, the larval gut 
becomes colonized by bacteria within a matter of hours (Jemielita et al., 2014). At the 
same time, the newly fated pancreatic beta cells begin to expand their numbers to meet 
the growing nutritional needs of the young fish (Moro et al., 2009). Similarly, humans are 
limited to bacterial exposures in the womb, but acquire a rich intestinal microbiota after 
birth, during the same period when beta cell mass is growing (Gregg et al., 2012; Mueller 
et al., 2015). From this work, we now know that microbial colonization with specific 
bacteria is required for robust beta cell expansion in larval zebrafish. This powerful 
model system provided us the high throughput platform required to systematically 
identify the microbial signal responsible for conveying this important phenotype. The 
genetic and imaging tools already available for studying zebrafish will be useful for 
continuing our research into uncovering the molecular mechanism through which the host 
senses and interprets BefA.  
One area of focus that zebrafish will lend a particular advantage is in observing 
the natural trafficking of BefA. With a combination of tools such as transgenic reporter 
lines (labeling important tissues like the pancreatic ducts) and fluorescently tagged BefA 
constructs, we can visualize the in vivo movement of BefA. This approach will also be 
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useful for observing how BefA interacts with beta cells, which could give us clues as to 
the host sensing machinery that is required. These experiments will be advantageous in 
designing methods of delivery for terrestrial organisms in order to study the effects of 
BefA in mammalian models, as well as for planning potential drug delivery mechanisms 
in humans. 
 The discovery of functionally conserved BefA homologs in human-associated 
bacteria is encouraging for the potential of BefA to be developed into a therapeutic some 
day. It suggests the possibility of a conserved signaling pathway that can be explored and 
exploited. Experiments that utilize mammalian beta cells will be an important next step to 
test the translational potential of BefA. For instance the addition of BefA to primary islet 
cultures from murine as well as primate and even human sources will provide a simple 
system to test whether the activity of BefA or its homologs is limited to zebrafish. One 
recent piece of evidence that mammalian beta cells require microbes during development 
is the finding that juvenile GF mice have significantly reduced beta cell mass compared 
to their CV counterparts. One obvious experiment would be to administer BefA to GF 
mice in order to test whether it can boost beta cell mass.  
 In addition to understanding whether BefA’s activity is restricted to specific 
vertebrate lineages, it will also be important to understand whether or not its activity is 
restricted developmentally. For instance, beta cells may have an expiration time on their 
ability to sense BefA. So far, we have shown that BefA is sufficient to induce beta cell 
proliferation during early larval stages, when these cells are naturally programmed to 
proliferate and expand. Adult beta cells are biologically different; they are largely 
quiescent, which may alter their responsiveness to BefA. The effectiveness of BefA at 
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different stages of life will be important in determining the extent of its therapeutic 
potential. Both zebrafish and mice would provide suitable platforms for investigating this 
question. There are good models of diabetes in mice whereby genetic lesions result in 
spontaneous autoimmune destruction of beta cells, allowing for study of the 
environmental influences on disease progression (Alam et al., 2011). For example the 
Blaser lab has found that early exposure to antibiotics in these mouse models results in a 
higher penetrance of disease (Cox and Blaser, 2014). In zebrafish, beta cell ablation 
models allow researchers to temporally control the destruction of beta cells and study the 
regenerative capacity of exogenous molecules at any developmental stage (Curado et al., 
2007).  
 Lastly, as a rare yet important product of the microbiota, BefA may be lost more 
easily from a less diverse host-associated community, an event that may have 
consequences for development and subsequently for host health. The befA gene, however, 
is rare in bacterial genomes and our current efforts have failed to detect it in 
metagenomic shotgun data, which only contain sequences from genomes of the most 
abundant species and widely conserved genes. To begin to understand whether this is a 
relevant hypothesis, we should design targeted search efforts for BefA within 
metagenomic samples taken from a spectrum of healthy, pre-diabetic and diabetic 
individuals. By correlating BefA abundance, or abundance of species that produce BefA, 
to host health status we might begin to understand whether it’s depletion or loss is a 
critical step in disease progression.    
 The discovery of BefA illustrates the vast potential waiting to be uncovered 
within the microbiota. Future studies across gnotobiotic systems will benefit from 
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learning more about this newly appreciated source of bioactive molecules, many of which 
have likely shaped the evolution of the animals containing them. I hope we will continue 
to be amazed by the discoveries surrounding this field for many years to come.   
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